title: Clearance of Hepatitis C Virus After Fixed-Dose Combination Ledipasvir/Sofosbuvir in an Adolescent Female With Decompensated Cirrhosis.
abstract: Currently the only Food and Drug Administration-approved treatment for children with chronic hepatitis C virus is pegylated interferon with ribavirin, which is associated with significant adverse effects and low sustained virologic response rates. In this report, we discuss the use of ledipasvir/sofosbuvir to treat an adolescent with cirrhosis secondary to chronic hepatitis C virus.
authors.affiliation: Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of California, San Francisco.
authors.forename: Sara K
authors.initials: SK
authors.lastname: Smith
authors.forename: Philip
authors.initials: P
authors.lastname: Rosenthal
mesh_terms: D000293:Adolescent; D000998:Antiviral Agents / Q000008:administration & dosage*; D001562:Benzimidazoles / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D005260:Female; D005449:Fluorenes / Q000008:administration & dosage*; D016174:Hepacivirus / Q000187:drug effects*; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D008103:Liver Cirrhosis / Q000188:drug therapy*; D000069474:Sofosbuvir / Q000008:administration & dosage*; D019562:Viral Load
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; C586541:ledipasvir; D000069474:Sofosbuvir